Gastrointestinal Cancer

James J. Lee, MD, PhD, Assistant Professor of Medicine, Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, discusses mismatched repair in colorectal cancer.

The FDA has assigned a priority review designation to MM-398 in combination with 5-fluorouracil and leucovorin for patients with metastatic pancreatic cancer following treatment with a gemcitabine-based therapy.

Second-line treatment with ramucirumab did not improve overall survival compared with placebo in the full population of patients with advanced hepatocellular carcinoma examined in the phase III REACH study.

Patients with chemorefractory KRAS wild-type metastatic colorectal cancer had a statistically significant improvement in overall survival when treated with panitumumab (Vectibix) versus best supportive care, according to data released from a phase IlI study.

The addition of PEGPH20 to standard nab-paclitaxel and gemcitabine improved progression-free survival by 4.9 months compared with the two agents alone in untreated patients with advanced pancreatic cancer who expressed high-levels of hyaluronan.

Many oncology professionals who treat patients on regorafenib are unfamiliar with how to manage and prevent hand-foot skin reaction.

Adding liver-direceted Yttrium-90 resin microspheres to frontline FOLFOX-based chemotherapy improved liver-specific progression-free survival by 7.9 months for patients with colorectal cancer with liver-dominant metastases.

Richard Goldberg, MD, Ohio State University Comprehensive Cancer Center-James Cancer Hospital, discusses PD-1 blockade in tumors with mismatch repair deficiency.

Angus Dalgleish, MD, FRCP, FRACP, FRCPath, FMedSci, professor, Department of Oncology, St. George's, University of London, discusses a study that examined the combination of an immunomodulator with gemcitabine in patients with pancreatic cancer.

The combination of dabrafenib, trametinib, and panitumumab showed promising clinical activity in BRAFV600E-mutated metastatic colorectal cancer.

Robert J. Mayer, MD, discusses pivotal phase III results for TAS-102 in colorectal cancer.

Dung T. Lee, MD, assistant professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses a biomarker for PD-1 agents in colorectal cancer (CRC).

Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the METGastric study.

Nivolumab generated antitumor responses in nearly 20% of patients with advanced HCC in a small study that suggests a promising role for the immunotherapy agent in a malignancy with dismal outcomes.

Treatment with the PD-1 inhibitor pembrolizumab demonstrated high response rates in patients with heavily pretreated colorectal cancer who harbored genetic defects in mismatch repair.